In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging

Luigi Aloj, M. Panico, C. Caraco, S. Del Vecchio, C. Arra, A. Affuso, A. Accardo, R. Mansi, D. Tesauro, S. De Luca, C. Pedone, R. Visentin, U. Mazzi, G. Morelli, M. Salvatore

Research output: Contribution to journalArticle

Abstract

Cholecystokinin (CCK) receptors of the subtype B (CCK-BR) have been shown to be overexpressed in certain neuroendocrine tumors including medullary thyroid cancer. Our recent work has focused on new methods to radiolabel the CCK8 peptide with 111In or 99mTc for CCK-B receptor imaging. Derivatives of CCK8 were obtained by addition at the N-terminus in solid phase of a DTPA derivative (DTPAGlu) linked through a glycine spacer (DTPAGlu-G-CCK8) or cysteine, glycine and a diphenylphosphinopropionyl moiety (PhosGC-CCK8) for labeling with 111In and 99mTc, respectively. CCK-BR overexpressing A431 cancer cell lines were utilized to characterize in vitro properties of the two compounds as well as for generating xenografts in nude mice for in vivo characterization. Both 111In-DTPAGlu-G-CCK8 and 99mTc-PhosGC-CCK8 showed similar binding affinities for CCK-BR with dissociation constants of 20-40 nM, were internalized after interaction with the receptor and displayed prolonged cellular retention times. Specific in vivo interaction with the receptor of both CCK8 analogs was observed in our animal model. 111In-DTPAGlu-G-CCK8 showed better target to non-target ratios, although it appeared to be rapidly metabolized after injection and activity cleared through the kidneys. 99mTc-PhosGC-CCK8 was more stable in vivo but showed marked hepatobiliary clearance with resulting high background activity in the bowel. The rapid clearance and lower background obtained with 111In-DTPAGlu-G-CCK8 make this a better candidate for further development.

Original languageEnglish
Pages (from-to)93-98
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume19
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Cholecystokinin B Receptor
Indium
Cholecystokinin
Technetium
Glycine
Pentetic Acid
Neuroendocrine Tumors
Heterografts
Nude Mice
Cysteine
Animal Models
Kidney
Cell Line
Peptides
Injections
In Vitro Techniques
cholecystokinin 8
indium DTPA-Glu-G-CCK8
Neoplasms

Keywords

  • Cholecystokinin receptors
  • Indium-111
  • Neuroendocrine tumors
  • Peptides
  • Technetium-99m

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging. / Aloj, Luigi; Panico, M.; Caraco, C.; Del Vecchio, S.; Arra, C.; Affuso, A.; Accardo, A.; Mansi, R.; Tesauro, D.; De Luca, S.; Pedone, C.; Visentin, R.; Mazzi, U.; Morelli, G.; Salvatore, M.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 19, No. 1, 2004, p. 93-98.

Research output: Contribution to journalArticle

Aloj, L, Panico, M, Caraco, C, Del Vecchio, S, Arra, C, Affuso, A, Accardo, A, Mansi, R, Tesauro, D, De Luca, S, Pedone, C, Visentin, R, Mazzi, U, Morelli, G & Salvatore, M 2004, 'In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging', Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 1, pp. 93-98. https://doi.org/10.1089/108497804773391739
Aloj, Luigi ; Panico, M. ; Caraco, C. ; Del Vecchio, S. ; Arra, C. ; Affuso, A. ; Accardo, A. ; Mansi, R. ; Tesauro, D. ; De Luca, S. ; Pedone, C. ; Visentin, R. ; Mazzi, U. ; Morelli, G. ; Salvatore, M. / In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging. In: Cancer Biotherapy and Radiopharmaceuticals. 2004 ; Vol. 19, No. 1. pp. 93-98.
@article{4c0fcb4b2c36472592221260fe7b7d2b,
title = "In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging",
abstract = "Cholecystokinin (CCK) receptors of the subtype B (CCK-BR) have been shown to be overexpressed in certain neuroendocrine tumors including medullary thyroid cancer. Our recent work has focused on new methods to radiolabel the CCK8 peptide with 111In or 99mTc for CCK-B receptor imaging. Derivatives of CCK8 were obtained by addition at the N-terminus in solid phase of a DTPA derivative (DTPAGlu) linked through a glycine spacer (DTPAGlu-G-CCK8) or cysteine, glycine and a diphenylphosphinopropionyl moiety (PhosGC-CCK8) for labeling with 111In and 99mTc, respectively. CCK-BR overexpressing A431 cancer cell lines were utilized to characterize in vitro properties of the two compounds as well as for generating xenografts in nude mice for in vivo characterization. Both 111In-DTPAGlu-G-CCK8 and 99mTc-PhosGC-CCK8 showed similar binding affinities for CCK-BR with dissociation constants of 20-40 nM, were internalized after interaction with the receptor and displayed prolonged cellular retention times. Specific in vivo interaction with the receptor of both CCK8 analogs was observed in our animal model. 111In-DTPAGlu-G-CCK8 showed better target to non-target ratios, although it appeared to be rapidly metabolized after injection and activity cleared through the kidneys. 99mTc-PhosGC-CCK8 was more stable in vivo but showed marked hepatobiliary clearance with resulting high background activity in the bowel. The rapid clearance and lower background obtained with 111In-DTPAGlu-G-CCK8 make this a better candidate for further development.",
keywords = "Cholecystokinin receptors, Indium-111, Neuroendocrine tumors, Peptides, Technetium-99m",
author = "Luigi Aloj and M. Panico and C. Caraco and {Del Vecchio}, S. and C. Arra and A. Affuso and A. Accardo and R. Mansi and D. Tesauro and {De Luca}, S. and C. Pedone and R. Visentin and U. Mazzi and G. Morelli and M. Salvatore",
year = "2004",
doi = "10.1089/108497804773391739",
language = "English",
volume = "19",
pages = "93--98",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - In Vitro and in Vivo Characterization of Indium-111 and Technetium-99m Labeled CCK-8 Derivatives for CCK-B Receptor Imaging

AU - Aloj, Luigi

AU - Panico, M.

AU - Caraco, C.

AU - Del Vecchio, S.

AU - Arra, C.

AU - Affuso, A.

AU - Accardo, A.

AU - Mansi, R.

AU - Tesauro, D.

AU - De Luca, S.

AU - Pedone, C.

AU - Visentin, R.

AU - Mazzi, U.

AU - Morelli, G.

AU - Salvatore, M.

PY - 2004

Y1 - 2004

N2 - Cholecystokinin (CCK) receptors of the subtype B (CCK-BR) have been shown to be overexpressed in certain neuroendocrine tumors including medullary thyroid cancer. Our recent work has focused on new methods to radiolabel the CCK8 peptide with 111In or 99mTc for CCK-B receptor imaging. Derivatives of CCK8 were obtained by addition at the N-terminus in solid phase of a DTPA derivative (DTPAGlu) linked through a glycine spacer (DTPAGlu-G-CCK8) or cysteine, glycine and a diphenylphosphinopropionyl moiety (PhosGC-CCK8) for labeling with 111In and 99mTc, respectively. CCK-BR overexpressing A431 cancer cell lines were utilized to characterize in vitro properties of the two compounds as well as for generating xenografts in nude mice for in vivo characterization. Both 111In-DTPAGlu-G-CCK8 and 99mTc-PhosGC-CCK8 showed similar binding affinities for CCK-BR with dissociation constants of 20-40 nM, were internalized after interaction with the receptor and displayed prolonged cellular retention times. Specific in vivo interaction with the receptor of both CCK8 analogs was observed in our animal model. 111In-DTPAGlu-G-CCK8 showed better target to non-target ratios, although it appeared to be rapidly metabolized after injection and activity cleared through the kidneys. 99mTc-PhosGC-CCK8 was more stable in vivo but showed marked hepatobiliary clearance with resulting high background activity in the bowel. The rapid clearance and lower background obtained with 111In-DTPAGlu-G-CCK8 make this a better candidate for further development.

AB - Cholecystokinin (CCK) receptors of the subtype B (CCK-BR) have been shown to be overexpressed in certain neuroendocrine tumors including medullary thyroid cancer. Our recent work has focused on new methods to radiolabel the CCK8 peptide with 111In or 99mTc for CCK-B receptor imaging. Derivatives of CCK8 were obtained by addition at the N-terminus in solid phase of a DTPA derivative (DTPAGlu) linked through a glycine spacer (DTPAGlu-G-CCK8) or cysteine, glycine and a diphenylphosphinopropionyl moiety (PhosGC-CCK8) for labeling with 111In and 99mTc, respectively. CCK-BR overexpressing A431 cancer cell lines were utilized to characterize in vitro properties of the two compounds as well as for generating xenografts in nude mice for in vivo characterization. Both 111In-DTPAGlu-G-CCK8 and 99mTc-PhosGC-CCK8 showed similar binding affinities for CCK-BR with dissociation constants of 20-40 nM, were internalized after interaction with the receptor and displayed prolonged cellular retention times. Specific in vivo interaction with the receptor of both CCK8 analogs was observed in our animal model. 111In-DTPAGlu-G-CCK8 showed better target to non-target ratios, although it appeared to be rapidly metabolized after injection and activity cleared through the kidneys. 99mTc-PhosGC-CCK8 was more stable in vivo but showed marked hepatobiliary clearance with resulting high background activity in the bowel. The rapid clearance and lower background obtained with 111In-DTPAGlu-G-CCK8 make this a better candidate for further development.

KW - Cholecystokinin receptors

KW - Indium-111

KW - Neuroendocrine tumors

KW - Peptides

KW - Technetium-99m

UR - http://www.scopus.com/inward/record.url?scp=12144286482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144286482&partnerID=8YFLogxK

U2 - 10.1089/108497804773391739

DO - 10.1089/108497804773391739

M3 - Article

C2 - 15068617

AN - SCOPUS:12144286482

VL - 19

SP - 93

EP - 98

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 1

ER -